The University Hospital of Gran Canaria Doctor Negrín has incorporated a new technique that has made it possible to carry out first seven unrelated allogeneic bone marrow transplants, that is, the modality in which there is no kinship between donor and recipient.
With this pilot project the possibilities of treatment are expanded and prevents patients from moving to the Peninsula for their attention, they added this Wednesday through a press release from the Ministry of Health of the Canary Islands Government.
The transplantation of hematopoietic progenitors (TPH) or bone marrow transplant can be autologous, when the patient himself is the donor; or allogeneic, the donor is another person; if it is a family member, it is called a related relative, and if it is an unknown, unrelated allogeneic person, they detailed the same sources before pointing out that the Negrín is the reference hospital for the Canary Islands, both for relational and non-related transplants.
The advancement was presented by the Health Minister of the Canary Islands Government, José Manuel Baltar, the managing director of Dr. Negrín, Pedro Rodríguez, the head of the hematology service, Teresa Molero, and Santiago Jiménez as a specialist of the transplant unit together. the first transplanted patient, Mercedes Domínguez.
The Minister of Health congratulated the professionals of hematology for the progress achieved after more than 20 years of effort and work with the best quality standards, which have placed this service "as one of the most outstanding in Spain to obtain in 2010, and renewed in 2016, the European accreditation Jacie in the areas of procurement, processing and implant in adults of hematopoietic progenitors "
In addition, Baltar added that the Negrin is incorporated into the network of 31 hospitals in Spain that perform non-related allogeneic transplants and Rodriguez showed his satisfaction for the progress achieved, possible "thanks to the good work of the professionals and their ongoing commitment to quality "of the grancanario hospital.
The chief of hematology and hemotherapy of Dr. Negrín stressed that "the service in 2018 a total of 74 transplants, of which 18 are allogenic, 17 haploidentical, 6 unrelated and 33 autologous. Haploidentical allogeneic transplants are those that patient and donor share histocompatibility antigens but are not identical. "
The Hospital Doctor Negrín is a reference center of the autonomous community of the Canary Islands in the realization of allogeneic transplantation (which includes the haploidentical) of adults, which is used mainly in pathologies such as aplastic anemia, acute leukemias, lymphomas and myelomas, besides practicing also the autologous (the patient is the donor himself).
Dr. Santiago Jiménez, on the other hand, explained that "in the unrelated transplant the hematopoietic progenitors to implant the patient come from the universal bank sponsored by the Spanish Registry of Bone Marrow Donors (Redmo)", so that the product arrives from any center in the world in a process similar to the grafting of solid organs, while in the case of relatives it is extracted in the same center through an apheresis process.
The patient Mercedes Domínguez expressed her "gratitude" to all professionals from the Hospital Doctor Negrín, highlighting its "good work and human quality", as well as assessing the gesture of the donor for the opportunity offered to enjoy a normal life.
To join and coordinate both the professionals and the processes of the transplant to improve the care of the haematological patient who is a candidate for transplantation of hematopoietic progenitors and their donors is the objective of the unit created in 2007.
In addition, the hematopoietic transplant unit offers the best possible service, treatment and support, with a personalized attention, since their hospitalization conditions are different from those of other patients, evaluated from Health before considering teamwork, participation of family members and patients is essential, as well as the collaboration of professionals who participate in national and international biological and clinical research protocols.